ClinicalTrials.gg
CompletedNCT01316900Updated Jan 24, 2018Results posted

24-week Trial Comparing GSK573719/GW642444 With GW642444 and With Tiotropium in Chronic Obstructive Pulmonary Disease

A Phase 3 interventional study of GSK573719/GW642444 125/25 and GSK573719/GW642444 62.5/25 in Pulmonary Disease, Chronic Obstructive, sponsored by GlaxoSmithKline. Completed at 97 sites in 10 countries. Open to participants aged 40 Years and older. Per ClinicalTrials.gov, last updated 2018-01-24.

Sponsored by GlaxoSmithKline · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
846
Allocation
Randomized
Ages
40 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 48 studies testing vilanterol in Pulmonary Disease, Chronic Obstructive — 2 open to participants now, 3 under way, 1 of them phase 3. vilanterol · Pulmonary Disease, Chronic Obstructive.

Enrollment
10th of 48
846 · median 168
Started
2011
with 7 others
Phase 3
19 of 48
none open now
Registered
19th of 48
by date
Lead sponsor
41 of 48
GlaxoSmithKline

Among the 48 studies testing vilanterol in Pulmonary Disease, Chronic Obstructive, this one is the 10th largest by enrollment, is one of 8 that started in 2011, is one of 19 in phase 3, and was the 19th registered.

Pulmonary Disease, Chronic Obstructive

5,523 studies on the registry are indexed under Pulmonary Disease, Chronic Obstructive; 856 are open to participants now.

Browse Pulmonary Disease, Chronic Obstructive studies →

Open to participants now

2 of the 48 studies testing vilanterol in Pulmonary Disease, Chronic Obstructive are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About vilanterol

vilanterol: first EMA approval 2013. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 558 Pulmonary Disease, Chronic Obstructive studies recruiting now, 307 (55%) set no upper age limit and 82 (15%) stop at 75 or younger; 29 take children under 18; 88 take healthy volunteers.

This study: 40 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 48 studies testing vilanterol in Pulmonary Disease, Chronic Obstructive, or all of them as a file.
02

Study summary

This is a Phase III multicenter, randomized, double-blind, double-dummy, parallel-group study to evaluate the efficacy and safety of two doses of GSK573719/GW642444 Inhalation Powder and GW642444 Inhalation Powder via a Novel Dry Powder Inhaler and tiotropium via HandiHaler when administered once-daily over a 24-week treatment period in subjects with chronic obstructive pulmonary disease (COPD). Subjects who meet eligibility criteria at Screening (Visit 1) will complete a 7 to10 day run-in period followed by a randomization visit (Visit 2) then a 24-week treatment period. There will be a total of 9 clinic study visits. A follow-up phone contact for adverse event assessment will be conducted approximately one week after the last study visit (Visit 9 or Early Withdrawal). The total duration of subject participation in the study will be approximately 26 weeks. The primary measure of efficacy is clinic visit trough (pre-bronchodilator and pre-dose) forced expiratory volume in one second (FEV1) on Treatment Day 169. Safety will be assessed by adverse events, 12-lead ECGs, vital signs, and clinical laboratory tests.

Read the detailed description

This is a 24-week, Phase III multicenter, randomized, double-blind, double-dummy, parallel-group study. Eligible subjects will be randomized to GSK573719/GW642444 125/25mcg, GSK573719/GW642444 62.5/25mcg, GW642444 25mcg, or tiotropium treatment groups in a 1:1:1:1 ratio. Treatments will be administered once-daily in the morning by inhalation using a Novel Dry Powder Inhaler (Novel DPI) and HandiHaler. There will be a total of 9 study clinic visits conducted on an outpatient basis. Subjects who meet the eligibility criteria at Screening (Visit 1) will complete a 7 to 10 day run-in period followed by a 24-week treatment period. Clinic visits will be at Screening, Randomization (Day 1), Day 2, after 4, 8, 12, 16, and 24-weeks of treatment, and 1 day after the Week 24 Visit (also referred as Treatment Day 169). A follow-up contact for adverse assessment will be conducted by telephone approximately 7 days after Visit 9 or the Early Withdrawal Visit. The total duration of subject participation, including follow-up will be approximately 26 weeks. All subjects will be provided with albuterol/salbutamol for use on an "as-needed" basis throughout the run-in and study treatment periods. At screening, pre-bronchodilator spirometry testing will be followed by post-albuterol/salbutamol spirometry testing. Post-albuterol/salbutamol FEV1 and FEV1/forced vital capacity (FVC) values will be used to determine subject eligibility. To further characterize bronchodilator responsiveness, post-ipratropium testing will be conducted following completion of post-albuterol/salbutamol spirometry. Spirometry will be conducted at each post-randomization clinic visit. Six hour post-dose serial spirometry will be conducted at Visits 2, 6, and 8. Trough spirometry will be obtained 23 and 24 hours after the previous day's dose of blinded study medication at Visits 3 to 9. All subjects will be provided with an electronic diary (eDiary) for completion daily in the morning and the evening throughout the run-in and treatment periods. Subjects will use the eDiary to record peak expiratory flow (PEF) each morning, dyspnea scores using the Shortness of Breath with Daily Activities instrument (SOBDA), daily use of supplemental albuterol/salbutamol as either puffs/day from a metered-dose inhaler (MDI) and/or nebules used per day, and any healthcare contacts related to COPD. Additional assessments of dyspnea will be obtained using the Baseline and Transition Dyspnea Index (BDI/TDI) which is an interviewer based instrument. At Visit 2, the severity of dyspnea at baseline will be assessed using the BDI. At subsequent visits (Visits 4, 6, and 8) change from baseline will be assessed using the TDI. General health status will be evaluated using the subject-completed EQ-5D questionnaire at Visits 2, 4, 6, and 8. Disease specific health status will be evaluated using the subject-completed St. George's Respiratory Questionnaire (SGRQ) at Visits 2, 4, 6, and 8, and the subject-completed COPD Assessment Test (CAT) at Visits 2, 6, and 8. The occurrence of adverse events will be evaluated throughout the study beginning at Visit 2. SAEs will be collected over the same time period as for AEs. However, any SAEs assessed as related to study participation (e.g., study treatment, protocol-mandated procedures, invasive tests, or change in existing therapy) or related to a GSK concomitant medication, will be recorded from the time a subject consents to participate in the study up to and including any follow up contact. Additional safety assessments of vital signs (blood pressure and pulse rate), 12-lead ECGs and standard clinical laboratory tests (hematology and chemistry) will be obtained at selected clinic visits.

03

Conditions studied

  • Pulmonary Disease, Chronic Obstructive

Keywords

  • long-acting muscarinic antagonist
  • tiotropium
  • COPD
  • long-acting beta agonist
04

Who can participate

Ages eligible
40 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • outpatient
  • signed and dated written
  • 40 years of age or older
  • male and female subjects
  • diagnosis
  • at least 10 pack-year smoking history
  • post-albuterol/salbutamol /FVC ratio of \<0.70 and post-albuterol/salbutamol FEV1 of less than or equal to 70% predicted normal values
  • score of greater than or equal to 2 on the Modified Medical Resarch Council Dyspnea Scale (mMRC)

Exclusion criteria

Exclusion Criteria:

  • women who are pregnant or lactating or are planning on becoming pregnant during the study
  • current diagnosis of asthma
  • other respiratory disorders other than
  • other diseases/abnormalities that are uncontrolled including cancer not in remission for at least 5 years
  • chest x-ray or CT scan with abnormalities not believed to be due to COPD
  • to anticholinergics, beta-agonists, lactose/milk protein or magnesium stearate or medical conditions associated with inhaled anticholinergics
  • hospitalization for COPD or pneumonia within 12 weeks prior to Visit 1
  • lung volume reduction surgery within 12 months prior to Visit 1
  • abnormal and clinically significant at Visit 1
  • significantly abnormal finding from laboratory tests at Visit 1
  • unable to withhold albuterol/salbutamol at least 4 hours prior to spirometry at each visit
  • use of depot within 12 weeks of Visit 1
  • use of oral or parenteral corticosteroids, antibiotics for lower respiratory tract infection, or cytochrome P450 3A4 inhibitors, within 6 weeks of Visit 1
  • use of long-acting beta-agonist (LABA)/inhaled corticosteroid (ICS) product if LABA/ICS therapy is discontinued withing 30 days of Visit 1
  • use of ICS at a dose of >1000mcg/day of fluticasone propionate or equivalent within 30 days of Visit 1
  • initiation or discontinuation of ICS within 30 days of Visit 1
  • use of tiotropium or roflumilast within 14 days of Visit 1
  • use of theophyllines, oral leukotriene inhibitors, long-acting oral beta-agonists, or inhaled long-acting beta-agonists within 48 hours of Visit 1
  • short-acting oral beta-agonists within 12 hours of Visit 1
  • use of LABA/ICS combination products only if discontinuing LABA therapy and switching to ICS monotherapy within 48 hours of Visit 1 for the LABA component
  • use of sodium cromoglycate or nedocromil sodium within 24 hours of Visit 1
  • use of inhaled short-acting beta-agonists, inhaled short-acting anticholinergics, or inhaled short-acting anticholinergic/short-acting beta-agonist combination products within 4 hours of Visit 1
  • use of any other medication within 30 days or 5 drug half-lives (whichever is longer)
  • long-term oxygen therapy prescribed for >12 hours per day
  • regular use of nebulized short-acting bronchodilators
  • participation in acute phase of pulmonary rehabilitation program
  • known or suspected history of alcohol or drug abse within 2 years prior to Visit 1
  • anyone affiliated with the investigator site (e.g., investigator, sub-investigator, study coordinator, employee of a participating investigator or study site, or immediate family member)
  • previous exposure to GSK573719, GSK573719/GW642444 combination, GW642444 (vilanterol), or fluticasone furoate/GW642444 combination
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
846 participants (actual)

Study arms

  • Experimental
    GSK573719/GW642444 125/25

    125/25 mcg once-daily

    Drug: GSK573719/GW642444 125/25

  • Experimental
    GSK573719/GW642444 62.5/25

    62.5/25 mcg once-daily

    Drug: GSK573719/GW642444 62.5/25

  • Experimental
    GW642444

    25 mcg once-daily

    Drug: GW642444

  • Active comparator
    tiotropium bromide

    18 mcg once-daily

    Drug: tiotropium bromide

Interventions

  • DrugGSK573719/GW642444 125/25

    125/25 mcg once-daily

    Also known as: GSK573719/vilanterol trifenatate

  • DrugGSK573719/GW642444 62.5/25

    62.5/26 mcg once-daily

    Also known as: GSK573719/vilanterol trifenatate

  • 25 mcg once-daily

    Also known as: vilanterol trifenatate

  • 18 mcg once-daily

06

What researchers measure

Primary outcomes

  1. Change From Baseline (BL) in Trough Forced Expiratory Volume in One Second (FEV1) on Day 169 (Week 24)

    FEV1 is a measure of lung function and is defined as the maximal amount of air that can be forcefully exhaled in one second. Trough FEV1 measurements were taken electronically by spirometry on Days 2, 28, 56, 84, 112, 168, and 169. Baseline is defined as the mean of the assessments made 30 minutes pre-dose and 5 minutes pre-dose on Treatment Day 1. Trough FEV1 is defined as the mean of the FEV1 values obtained at 23 and 24 hours after the previous morning's dosing (ie., trough FEV1 on Day 169 is the mean of the FEV1 values obtained 23 and 24 hours after the morning dosing on Day 168). Change from Baseline at a particular visit was calculated as the trough FEV1 at that visit minus Baseline. Analysis was performed using a repeated measures model with covariates of treatment, Baseline , smoking status, center group, day, and day by Baseline and day by treatment interactions. ITT=Intent-to-Treat; par.=participants. .

    Time frame: Baseline and Day 169

Secondary outcomes

  1. Change From Baseline (BL) in Weighted Mean (WM) 0-6 Hour FEV1 Obtained Post-dose at Day 168

    FEV1 is a measure of lung function and is defined as the maximal amount of air that can be forcefully exhaled in one second. The WM FEV1 was derived by calculating the area under the FEV1/time curve (AUC) using the trapezoidal rule, and then dividing the value by the time interval over which the AUC was calculated. The WM was calculated at Days 1, 84, and Day 168 using the 0-6-hour post-dose FEV1 measurements collected on that day, which included pre-dose (Day 1: 30 minutes \[min\] and 5 min prior to dosing; other serial visits: 23 and 24 hours after the previous morning dose) and post-dose at 15 minutes, 30 minutes, 1 hour, 3 hours, and 6 hours. Change from BL at a particular visit was calculated as WM at that visit minus BL. Analysis was performed using a repeated measures model with covariates of treatment, BL (mean of the two assessments made 30 minutes and 5 minutes pre-dose on Day 1), smoking status, center group, day, and day by BL and day by treatment interactions.

    Time frame: Baseline and Day 168

Other outcomes

  1. Change From Baseline (BL) in the Mean Shortness of Breath With Daily Activities (SOBDA) Score for Week 24

    The newly developed SOBDA questionnaire assesses dyspnea or shortness of breath (SOB) with daily activities. The SOBDA questionnaire is made up of 13 items completed by the participant (par.) each evening prior to bedtime, when the par. is instructed to reflect on the current day's activities. The daily score is computed as the mean of the scores on the 13 items (\>=7 items must have non-missing responses for this to be calculated). The par. is assigned a weekly mean SOBDA score ranging from 1 to 4 (greater scores indicate more severe breathlessness with daily activities) based on the mean of 7 days of data (\>=4 of 7 days must be completed for a weekly mean to be calculated). Change from BL is the mean weekly SOBDA score minus BL. Analysis was performed using MMRM with covariates of treatment, BL (mean score in the week prior to treatment), smoking status, center group, week, week by BL and week by treatment interactions. This MMRM analysis only included Weeks 4, 8, 12, and 24.

    Time frame: Baseline and Week 24

07

Results

Posted Feb 10, 2014

Participant flow

Participant flow — Overall Study
MilestoneVI 25 µgUMEC/VI 62.5/25 µgUMEC/VI 125/25 µgTIO 18 µg
Started209212214208
Completed165181173177
Not completed44314131
Withdrew: Adverse event1010159
Withdrew: Lack of efficacy17957
Withdrew: Protocol violation7140
Withdrew: Protocol-defined stopping criteria23105
Withdrew: Lost to follow-up1011
Withdrew: Withdrawal by subject7869

Outcome measures

PrimaryChange From Baseline (BL) in Trough Forced Expiratory Volume in One Second (FEV1) on Day 169 (Week 24)

FEV1 is a measure of lung function and is defined as the maximal amount of air that can be forcefully exhaled in one second. Trough FEV1 measurements were taken electronically by spirometry on Days 2, 28, 56, 84, 112, 168, and 169. Baseline is defined as the mean of the assessments made 30 minutes pre-dose and 5 minutes pre-dose on Treatment Day 1. Trough FEV1 is defined as the mean of the FEV1 values obtained at 23 and 24 hours after the previous morning's dosing (ie., trough FEV1 on Day 169 is the mean of the FEV1 values obtained 23 and 24 hours after the morning dosing on Day 168). Change from Baseline at a particular visit was calculated as the trough FEV1 at that visit minus Baseline. Analysis was performed using a repeated measures model with covariates of treatment, Baseline , smoking status, center group, day, and day by Baseline and day by treatment interactions. ITT=Intent-to-Treat; par.=participants. .

Time frame:
Baseline and Day 169
Reported as:
Least squares mean · Liters
Change From Baseline (BL) in Trough Forced Expiratory Volume in One Second (FEV1) on Day 169 (Week 24)
LitersVI 25 µgUMEC/VI 62.5/25 µgUMEC/VI 125/25 µgTIO 18 µg
Change From Baseline (BL) in Trough Forced Expiratory Volume in One Second (FEV1) on Day 169 (Week 24)0.121 ± 0.01890.211 ± 0.01830.209 ± 0.01870.121 ± 0.0186
Statistical analysis
  • VI 25 µg vs UMEC/VI 62.5/25 µg · Mixed Models Analysis · p = <0.001 · Least squares mean difference: 0.090 · 95% CI 0.039 to 0.142Least squares mean difference=UMEC/VI 62.5/25 µg minus VI 25 µg.
  • UMEC/VI 62.5/25 µg vs TIO 18 µg · Mixed Models Analysis · p = <0.001 (nominal p-value) · Least squares mean difference: 0.090 · 95% CI 0.039 to 0.141Least squares mean difference=UMEC/VI 62.5/25 µg minus Tio 18 µg.
  • VI 25 µg vs UMEC/VI 125/25 µg · Mixed Models Analysis · p = <0.001 · Least squares mean difference: 0.088 · 95% CI 0.036 to 0.140Least squares mean difference=UMEC/VI 125/25 µg minus VI 25 µg.
  • UMEC/VI 125/25 µg vs TIO 18 µg · Mixed Models Analysis · p = <0.001 · Least squares mean difference: 0.088 · 95% CI 0.036 to 0.140Least squares mean difference=UMEC/VI 125/25 µg minus TIO 18 µg.
SecondaryChange From Baseline (BL) in Weighted Mean (WM) 0-6 Hour FEV1 Obtained Post-dose at Day 168

FEV1 is a measure of lung function and is defined as the maximal amount of air that can be forcefully exhaled in one second. The WM FEV1 was derived by calculating the area under the FEV1/time curve (AUC) using the trapezoidal rule, and then dividing the value by the time interval over which the AUC was calculated. The WM was calculated at Days 1, 84, and Day 168 using the 0-6-hour post-dose FEV1 measurements collected on that day, which included pre-dose (Day 1: 30 minutes \[min\] and 5 min prior to dosing; other serial visits: 23 and 24 hours after the previous morning dose) and post-dose at 15 minutes, 30 minutes, 1 hour, 3 hours, and 6 hours. Change from BL at a particular visit was calculated as WM at that visit minus BL. Analysis was performed using a repeated measures model with covariates of treatment, BL (mean of the two assessments made 30 minutes and 5 minutes pre-dose on Day 1), smoking status, center group, day, and day by BL and day by treatment interactions.

Time frame:
Baseline and Day 168
Reported as:
Least squares mean · Liters
Change From Baseline (BL) in Weighted Mean (WM) 0-6 Hour FEV1 Obtained Post-dose at Day 168
LitersVI 25 µgUMEC/VI 62.5/25 µgUMEC/VI 125/25 µgTIO 18 µg
Change From Baseline (BL) in Weighted Mean (WM) 0-6 Hour FEV1 Obtained Post-dose at Day 1680.178 ± 0.01890.254 ± 0.01830.263 ± 0.01870.181 ± 0.0187
Other pre-specifiedChange From Baseline (BL) in the Mean Shortness of Breath With Daily Activities (SOBDA) Score for Week 24

The newly developed SOBDA questionnaire assesses dyspnea or shortness of breath (SOB) with daily activities. The SOBDA questionnaire is made up of 13 items completed by the participant (par.) each evening prior to bedtime, when the par. is instructed to reflect on the current day's activities. The daily score is computed as the mean of the scores on the 13 items (\>=7 items must have non-missing responses for this to be calculated). The par. is assigned a weekly mean SOBDA score ranging from 1 to 4 (greater scores indicate more severe breathlessness with daily activities) based on the mean of 7 days of data (\>=4 of 7 days must be completed for a weekly mean to be calculated). Change from BL is the mean weekly SOBDA score minus BL. Analysis was performed using MMRM with covariates of treatment, BL (mean score in the week prior to treatment), smoking status, center group, week, week by BL and week by treatment interactions. This MMRM analysis only included Weeks 4, 8, 12, and 24.

Time frame:
Baseline and Week 24
Reported as:
Least squares mean · Scores on a scale
Change From Baseline (BL) in the Mean Shortness of Breath With Daily Activities (SOBDA) Score for Week 24
Scores on a scaleVI 25 µgUMEC/VI 62.5/25 µgUMEC/VI 125/25 µgTIO 18 µg
Change From Baseline (BL) in the Mean Shortness of Breath With Daily Activities (SOBDA) Score for Week 24-0.16 ± 0.043-0.18 ± 0.042-0.18 ± 0.044-0.18 ± 0.044

Adverse events

Collected over On-treatment serious adverse events (SAEs) and non-serious adverse events (AEs) were collected from the start of study medication until the end of treatment (up to 24 weeks).. Non-serious events are listed at a 3% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
VI 25 µg—15/209 (7.2%)44/209 (21.1%)
UMEC/VI 62.5/25 µg—7/212 (3.3%)54/212 (25.5%)
UMEC/VI 125/25 µg—5/214 (2.3%)40/214 (18.7%)
TIO 18 µg—13/208 (6.3%)37/208 (17.8%)
Most frequent serious events
Showing 10 of 33
Most frequent serious events
EventVI 25 µgUMEC/VI 62.5/25 µgUMEC/VI 125/25 µgTIO 18 µg
Chronic obstructive pulmonary diseaseRespiratory, thoracic and mediastinal disorders2/2095/2123/2143/208
PneumoniaInfections and infestations1/2090/2120/2142/208
Non-cardiac chest painGeneral disorders0/2090/2120/2142/208
GastroenteritisInfections and infestations0/2090/2120/2141/208
OsteomyelitisInfections and infestations0/2090/2120/2141/208
Urinary tract infectionInfections and infestations0/2090/2120/2141/208
Craniocerebral injuryInjury, poisoning and procedural complications0/2090/2120/2141/208
Lumbar vertebral fractureInjury, poisoning and procedural complications0/2090/2120/2141/208
Vascular graft occlusionInjury, poisoning and procedural complications0/2090/2120/2141/208
WoundInjury, poisoning and procedural complications0/2090/2120/2141/208
Most frequent other events
Most frequent other events
EventVI 25 µgUMEC/VI 62.5/25 µgUMEC/VI 125/25 µgTIO 18 µg
HeadacheNervous system disorders21/20920/21214/2149/208
NasopharyngitisInfections and infestations17/20921/21214/21416/208
Back painMusculoskeletal and connective tissue disorders3/20910/2127/2144/208
Upper respiratory tract infectionInfections and infestations5/2098/2127/2148/208
CoughRespiratory, thoracic and mediastinal disorders4/2097/2127/2145/208

Baseline characteristics

Age, Continuous
Age, Continuous(Years)VI 25 µgUMEC/VI 62.5/25 µgUMEC/VI 125/25 µgTiotropium 18 µgTotal
Mean63.2 ± 9.1063.0 ± 8.6762.9 ± 8.8762.6 ± 9.3962.9 ± 9.00
Sex: Female, Male
Sex: Female, Male(Participants)VI 25 µgUMEC/VI 62.5/25 µgUMEC/VI 125/25 µgTiotropium 18 µgTotal
Female66646368261
Male143148151140582
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)VI 25 µgUMEC/VI 62.5/25 µgUMEC/VI 125/25 µgTiotropium 18 µgTotal
African American/African Heritage379625
American Indian or Alaska Native1916212076
Asian - Central/South Asian Heritage00101
Asian - Japanese Heritage03025
White - White/Caucasian/European Heritage184182180177723
Mixed Race343313
08

Study locations

97 sites
  • GSK Investigational Site
    Birmingham, Alabama 35216, United States
  • GSK Investigational Site
    San Diego, California 92117, United States
  • GSK Investigational Site
    DeLand, Florida 32720, United States
  • GSK Investigational Site
    Orlando, Florida 32822, United States
  • GSK Investigational Site
    Tampa, Florida 33603, United States
  • GSK Investigational Site
    Decatur, Georgia 30033, United States
  • GSK Investigational Site
    Saint Charles, Missouri 63301, United States
  • GSK Investigational Site
    Albuquerque, New Mexico 87108, United States
  • GSK Investigational Site
    Oklahoma City, Oklahoma 73103, United States
  • GSK Investigational Site
    Phoenixville, Pennsylvania 19460, United States
  • GSK Investigational Site
    Charleston, South Carolina 29406-7108, United States
  • GSK Investigational Site
    Gaffney, South Carolina 29340, United States
  • GSK Investigational Site
    Greenville, South Carolina 29615, United States
  • GSK Investigational Site
    Rock Hill, South Carolina 29732, United States
  • GSK Investigational Site
    Seneca, South Carolina 29678, United States
  • GSK Investigational Site
    Rapid City, South Dakota 57702, United States
  • GSK Investigational Site
    San Antonio, Texas 78229, United States
  • GSK Investigational Site
    Newport News, Virginia 23606, United States
  • GSK Investigational Site
    Richmond, Virginia 23229, United States
  • GSK Investigational Site
    Clermont Ferrand cedex 1, 63003, France
  • GSK Investigational Site
    Nantes cedex 1, 44093, France
  • GSK Investigational Site
    Nîmes cedex 09, 30029, France
  • GSK Investigational Site
    Saint Pierre Cedex, 97448, France
  • GSK Investigational Site
    Sinsheim, Baden-Wuerttemberg 74889, Germany
  • GSK Investigational Site
    Stuttgart, Baden-Wuerttemberg 70378, Germany
  • GSK Investigational Site
    Bamberg, Bayern 96049, Germany
  • GSK Investigational Site
    Erlangen, Bayern 91052, Germany
  • GSK Investigational Site
    Muenchen, Bayern 80339, Germany
  • GSK Investigational Site
    Nuernberg, Bayern 90402, Germany
  • GSK Investigational Site
    Potsdam, Brandenburg 14467, Germany
  • GSK Investigational Site
    Marburg, Hessen 35037, Germany
  • GSK Investigational Site
    Hannover, Niedersachsen 30159, Germany
  • GSK Investigational Site
    Hannover, Niedersachsen 30173, Germany
  • GSK Investigational Site
    Dortmund, Nordrhein-Westfalen 44147, Germany
  • GSK Investigational Site
    Dortmund, Nordrhein-Westfalen 44263, Germany
  • GSK Investigational Site
    Berlin, 10717, Germany
  • GSK Investigational Site
    Berlin, 12157, Germany
  • GSK Investigational Site
    Berlin, 12203, Germany
  • GSK Investigational Site
    Berlin, 13086, Germany
  • GSK Investigational Site
    Hamburg, 22299, Germany
  • GSK Investigational Site
    Avellino, Campania 83100, Italy
  • GSK Investigational Site
    Pordenone, Friuli-Venezia-Giulia 33170, Italy
  • GSK Investigational Site
    Roma, Lazio 00144, Italy
  • GSK Investigational Site
    Pietra Ligure (SV), Liguria 17027, Italy
  • GSK Investigational Site
    Milano, Lombardia 20121, Italy
  • GSK Investigational Site
    Pavia, Lombardia 27100, Italy
  • GSK Investigational Site
    Tradate (VA), Lombardia 21049, Italy
  • GSK Investigational Site
    Foggia, Puglia 71100, Italy
  • GSK Investigational Site
    Catania, Sicilia 95123, Italy
  • GSK Investigational Site
    Pisa, Toscana 56124, Italy
  • GSK Investigational Site
    Guadalajara, Jalisco 44100, Mexico
  • GSK Investigational Site
    Zapopan, Jalisco 45200, Mexico
  • GSK Investigational Site
    Mexico City, 07760, Mexico
  • GSK Investigational Site
    Mexico, 10700, Mexico
  • GSK Investigational Site
    Jesus Maria, Lima Lima 11, Peru
  • GSK Investigational Site
    Lima 27, Lima Lima 27, Peru
  • GSK Investigational Site
    San Borja, Lima Lima 41, Peru
  • GSK Investigational Site
    San Isidro, Lima Lima 27, Peru
  • GSK Investigational Site
    San Miguel, Lima Lima 32, Peru
  • GSK Investigational Site
    Santiago de Surco, Lima Lima 33, Peru
  • GSK Investigational Site
    Callao, Callao 2, Peru
  • GSK Investigational Site
    Lima, Lima 1, Peru
  • GSK Investigational Site
    Gdansk, 80-405, Poland
  • GSK Investigational Site
    Gidle, 97-540, Poland
  • GSK Investigational Site
    Krakow, 31-023, Poland
  • GSK Investigational Site
    Lubliniec, 42-700, Poland
  • GSK Investigational Site
    Sopot, 81-741, Poland
  • GSK Investigational Site
    Wloclawek, 87-800, Poland
  • GSK Investigational Site
    Zabrze, 41-800, Poland
  • GSK Investigational Site
    Bacau, 600252, Romania
  • GSK Investigational Site
    Bucharest, 011794, Romania
  • GSK Investigational Site
    Ploiesti, 100184, Romania
  • GSK Investigational Site
    Timisoara, 300310, Romania
  • GSK Investigational Site
    Chita, 672000, Russian Federation
  • GSK Investigational Site
    Irkutsk, 664005, Russian Federation
  • GSK Investigational Site
    Moscow, 115446, Russian Federation
  • GSK Investigational Site
    Petrozavodsk, 185019, Russian Federation
  • GSK Investigational Site
    Ryazan, 390039, Russian Federation
  • GSK Investigational Site
    Saint-Petersburg, 194354, Russian Federation
  • GSK Investigational Site
    Saratov, 410018, Russian Federation
  • GSK Investigational Site
    Saratov, 410028, Russian Federation
  • GSK Investigational Site
    Tomsk, 634001, Russian Federation
  • GSK Investigational Site
    Voronezh, 394018, Russian Federation
  • GSK Investigational Site
    Yaroslavl, Russian Federation
  • GSK Investigational Site
    Dnipropetrovsk, 49027, Ukraine
  • GSK Investigational Site
    Dnipropetrovsk, 49074, Ukraine
  • GSK Investigational Site
    Donetsk, 83099, Ukraine
  • GSK Investigational Site
    Ivano-Frankivsk, 76018, Ukraine
  • GSK Investigational Site
    Kharkiv, 61037, Ukraine
  • GSK Investigational Site
    Kharkiv, 61124, Ukraine
  • GSK Investigational Site
    Kiev, 03680, Ukraine
  • GSK Investigational Site
    Kyiv, 01114, Ukraine
  • GSK Investigational Site
    Kyiv, 03038, Ukraine
  • GSK Investigational Site
    Kyiv, 03680, Ukraine
  • GSK Investigational Site
    Simferopol, 95043, Ukraine
  • GSK Investigational Site
    Vinnytsia, 21029, Ukraine
  • GSK Investigational Site
    Zaporizhia, 69035, Ukraine
09

References and documents

Publications

  • Maleki-Yazdi MR, Singh D, Anzueto A, Tombs L, Fahy WA, Naya I. Assessing Short-term Deterioration in Maintenance-naive Patients with COPD Receiving Umeclidinium/Vilanterol and Tiotropium: A Pooled Analysis of Three Randomized Trials. Adv Ther. 2017 Jan;33(12):2188-2199. doi: 10.1007/s12325-016-0430-6. Epub 2016 Oct 28. PubMed 27796912 ↗
  • Decramer M, Anzueto A, Kerwin E, Kaelin T, Richard N, Crater G, Tabberer M, Harris S, Church A. Efficacy and safety of umeclidinium plus vilanterol versus tiotropium, vilanterol, or umeclidinium monotherapies over 24 weeks in patients with chronic obstructive pulmonary disease: results from two multicentre, blinded, randomised controlled trials. Lancet Respir Med. 2014 Jun;2(6):472-86. doi: 10.1016/S2213-2600(14)70065-7. Epub 2014 May 14. PubMed 24835833 ↗

Individual participant data

Plan to share: Yes — Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Mar 2011, a primary completion of Apr 2012 and a completion of Apr 2012. It does not say whether these dates are actual or estimated.

Results were first posted in Feb 2014, 1 year 10 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 15, 2011
First posted
Mar 16, 2011
Start
Mar 1, 2011
Primary completionActual
Apr 1, 2012
CompletionActual
Apr 24, 2012
Results first posted
Feb 10, 2014
Last update
Jan 24, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 24, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01316900
Lead sponsor
GlaxoSmithKline
Responsible party
Sponsor
First posted
Mar 16, 2011
Start date
Mar 1, 2011
Primary completion
Apr 1, 2012
Completion
Apr 24, 2012
Results posted
Feb 10, 2014
Last update
Jan 24, 2018

Study contacts

GSK Clinical Trials
study director · GlaxoSmithKline

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Vilanterol

Start the discussion